A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 9, 2015

Primary Completion Date

January 3, 2018

Study Completion Date

January 3, 2018

Conditions

Antitrypsin Deficiency Liver Disease

Interventions

DRUG

ALN-AAT

Single or multiple doses of ALN-AAT by subcutaneous (sc) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

calculated volume to match active comparator

Trial Locations (1)

Richmond Pharmacology, Ltd., London